WovenX is rebuilding specialty-care access by pairing a virtual bench of specialty-trained Advanced Practice Providers (APPs) with brick-and-mortar practices and health systems — starting with the sector's largest access bottleneck (gastroenterology) and now expanding to urology. The wedge is not "another telehealth app": WovenX slots in as a white-labeled capacity layer for existing GI groups and hospitals so patients get on-demand specialist triage in minutes instead of the industry-standard multi-month wait, with the sponsoring practice keeping the patient and the downstream procedure.
Validation is real and B2B: profitability first hit November 2024 with two hospital sites live and revenue growing 38% month-over-month Internal; ARR reached $2.6M by October 2025 Internal; named partnerships include Washington Gastroenterology (Nov 2024) Web, St. Charles Health System in Central Oregon Web, CRH Medical (WELL Health subsidiary) Web, and Idaho Gastroenterology Associates Web. StoryHouse Fund I led no round but took a $100K allocation on a $2M / $8M-post SAFE alongside Corazon Capital (Feb 2025) and — per the July 2026 priced Seed — has already marked at ~2x on paper as the SAFE converted at a $0.3475 share price into a round done at $0.6390 Internal.
Access is the binding constraint in U.S. specialty care: fragmented practices, retiring physicians, and multi-month waits. Telehealth is compounding at ~25% CAGR through 2035 Web, with specialty-care segments expected to lead the next wave after the first primary-care and behavioral-health waves. WovenX is going after that specialty layer from the provider side rather than the payer side, which lets it monetize immediately on services + subscription without a multi-year insurance-contracting cycle.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| WovenX Health | Provider-side white-labeled specialty APP network + on-demand platform for GI, expanding to urology | Pre-Seed $2M @ $8M SAFE; Seed July 2026 $4.7M @ $16M pre | — |
| Oshi Health | Payer-contracted virtual GI clinic (D2C via employer/health plan) | Series C $60M Oct 2024; $119.5M totalWeb | WovenX sells to the practice/hospital that Oshi's model routes patients away from — complementary channel, opposite side of the flow |
| PE-backed GI rollups (GI Alliance, US Digestive, etc.) | Physical multi-state GI platforms; consolidating supply | GI Alliance sold to Cardinal Health for $2.8B (Nov 2024)Web | Buyers of WovenX's capacity layer, not substitutes — US Digestive Health is already a WovenX customerWeb |
| In-house health-system telehealth teams | DIY specialty triage built inside IDNs | N/A | WovenX arrives turnkey with a trained specialty APP bench that a health system can't easily build; St. Charles and Washington Gastro chose "buy" over "build" |
Moat: The specialty APP bench itself — trained, credentialed, multi-state, and coupled to an AI-assisted intake/triage workflow — is the hardest input to reproduce, and it becomes more valuable per-hospital as the network of partner practices grows.
Comparable liquidity precedent: Cardinal Health's $2.8B acquisition of GI Alliance in November 2024 Web shows both the strategic appetite and the price-per-scale in GI. Natural acquirers for WovenX: (i) diversified payer/pharmacy platforms buying provider-side capacity (Cardinal, CVS Health), (ii) PE-backed specialty rollups needing a virtual-care layer (US Digestive, GI Alliance), and (iii) telehealth infrastructure players consolidating specialty verticals. At a $8M SAFE entry converting into a $16M-pre Seed Internal, the fund is already at ~2x paper markup with the return path largely a function of how many specialties Woven scales past GI.
Quarterly portfolio review with Sheri. Company has scaled to $2.6M ARR with 12 months of runway on a zero-growth basis; plans to fundraise in Q2 or Q3 2026 targeting $4–5M ARR at pitch.
Catch-up call with Sheri and WovenX for Q3 as part of our portfolio review. They can now see >1K OnDemand patients in a month last month. Started piloting bringing top-performing clinicians full-time from contractor and it's been working. Brought on a great new CoS who has helped significantly.
At $2.6M in ARR right now; with zero growth cash through October — 12 months. Thinks Q2 or Q3 fundraise next year. Serious gross-margin expansion this past quarter. RFI Exact Sciences which could be a big deal. New health system in Idaho to start in Jan. Wants help with ICP scrapes for Claremont. Launching Urology Platform Product shortly.
Business performance: $2.6M ARR, need to hit $4–5M for strong fundraising position; 12 months runway with zero growth (through Oct 2026); Q2 2026 fundraise target, possibly Q3. Growth drivers: new January deal, Loyola conversion from staffing to on-demand (temporary dip then growth), Q4 marketing pilots, margin expansion accelerating faster than revenue, legacy low-margin staffing customers reducing, on-demand higher-margin business increasing, AI tools reduced visit time 21→16.5 min, software revenue growing.
Strategic initiatives: Urology expansion critical for multi-specialty capability; Exact Sciences partnership potential (600K patients/year needing colonoscopy referrals) — 3-year relationship, now formal RFI where Woven is front-runner. Marketing partnership with Vibrant (Israeli constipation-pill D2C) — connecting their patients to Woven's Illinois OnDemand.
AI positioning: feedback that they need to be more "splashy" about AI integration despite deep implementation; investors want generative-AI companies, not AI-enhanced services. Plan to refine messaging in Q1 before fundraising.
Sheri walked through the finalized round: Corazon Capital led at $1M on the $2M / $8M-post SAFE with 25% discount, the founders opted for Corazon over other $10M-post term sheets on network fit, and StoryHouse was allocated $100K firm with possible upside.
Call with Sheri to discuss the Corazon term sheet and our allocation. She said they will push the strategic down and let us in for $100K for sure, and possibly would be open to another $50K but will let us know. Planning to close Wednesday and have all wires by Thursday of next week.
Corazon was pretty inflexible on price, but they did settle in the middle on a few other items like board and employee option pool. They ended up getting a few other term sheets at $10M, but they really like the Corazon team and think they are the best connected and networked to help them so they decided to go with them.
Allocations: Corazon $1M · Strategic Healthcare Group $350K · Hyde Park Angels $500K (they do a lot of healthcare and made the initial intro to Corazon) · $50K previous investors · $100K StoryHouse. Round terms: $2M round on $8M post SAFE.
Sheri flagged that WovenX had received a term sheet from Corazon Capital and was weighing whether to accept or push back for a $10M post with a 25% discount.
Sheri reached out for a call given they are far along with another investor and got a term sheet. Focusing more on on-demand revenue right now. Term sheet from Corazon Capital (OKCupid/Match/marketplace investors) — Chicago group, not healthcare-focused, but Sam the partner is on Rush board. Marketplace-focused group, Seed and Series A.
Round dynamics: SAFE round — raising $1.5–2M, Corazon putting in $1M, $8M post with 20% discount as starting point. Company planning to push back for $10M post with 25% discount.